Trial
NCT03627403
Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Utah
Collaborators
Karyopharm Therapeutics Inc
Condition
Primary Myelofibrosis
Intervention
Selinexor
Why stopped
PI and Sponsor decision. Accrual was low and there was sufficient data to detect a response.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-08